Author:
Daniele Stella M,Montenegro Silvana M,Tarres María C,Picena Juan C,Martinez Stella M
Abstract
Abstract
Background
eSS is a rat model of type 2 diabetes characterized by fasting hyperglycemia, glucose intolerance, hyperinsulinemia and early hypertriglyceridemia. Diabetic symptoms worsen during the second year of life as insulin release decreases. In 12-month-old males a diffuse hepatic steatosis was detected. We report the disturbances of lipid metabolism of the model with regard to the diabetic syndrome.
Methods
The study was conducted in eight 12-month-old eSS male rats and seven age/weight matched eumetabolic Wistar rats fed with a complete commercial diet al libitum. Fasting plasmatic glucose, insulin, triglycerides, total cholesterol, low-density and high-density lipoprotein, and nonesterified fatty acids levels were measured. Very low density and intermediate-density lipoproteins were analyzed and hepatic lipase activity was determined.
Results
eSS rats developed hyperglycemia and hyperinsulinemia, indicating insulin resistance. Compared with controls, diabetic rats exhibited high plasmatic levels of NEFA, triglycerides (TG), total cholesterol (Chol) and LDL-Chol while high-density lipoprotein (HDL) cholesterol values were reduced. eSS rats also displayed TG-rich VLDL and IDL particles without changes in hepatic lipase activity.
Conclusion
The nonobese eSS rats develop a syndrome characterized by glucose and lipid disorders and hepatic steatosis that may provide new opportunities for studying the pathogenesis of human type 2 diabetes.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference40 articles.
1. Boucher A, Lu D, Burgess SC, Telemaque-Potts S, Jensen MV, Mulder H, Wang M-Y, Roger H, Unger RH, Sherry D, Negar CB: Biochemical mechanism of lipid-induced impairment of glucosestimulated insulin secretion and reversal with a malate analogue. J Biol Chem. 2004, 279: 27263-27271. 10.1074/jbc.M401167200.
2. Kobayashi J, Nohara A, Kawashiri MA, Inazu A, Koizumi J, Nakajima K, Mabuchi H: Serum lipoprotein lipase mass: Clinical significance of its measurement. Clin Chim Acta. 2007, 378: 7-12. 10.1016/j.cca.2006.12.003.
3. Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003, 5 (Suppl 1): 19-27. 10.1046/j.1462-8902.2003.0310.x.
4. van Hateren KJ, Landman GW, Kleefstra N, Logtenberg SJ, Groenier KH, Kamper AM, Houweling ST, Bilo HJ: The lipid profile and mortality risk in elderly type 2 diabetic patients: a ten-year follow-up study (ZODIAC-13). PLoS One. 2009, 4: e8464-10.1371/journal.pone.0008464.
5. Martinez SM, Tarres MC, Picena JC, Montenegro SM, Gagliardino JJ, Gomez Dumm CL, D'Ottavio AE, Naves A, Rabasa SL: eSS rat, an animal model for the study of spontaneous non-insulin-dependent diabetes. Lessons from Animal Diabetes IV. Edited by: Eleazar Shafrir. 1993, London: Smith-Gordon, 75-90. 1
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献